Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Ashburn, Virginia, September 22nd, 2026, FinanceWire

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has No Approved Treatment

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. Peeling Skin Syndrome is a rare genetic skin disease for which there is currently no approved treatment.

Key Facts

  • Fast Track Designation applies to QRX003 for the treatment of Peeling Skin Syndrome.
  • This is the first ever Fast Track Designation granted for a Peeling Skin Syndrome therapy.
  • Peeling Skin Syndrome is the second indication for which QRX003 has received Fast Track Designation. The FDA granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome on March 11, 2026.
  • The designation follows FDA clearance in July 2026 of Quoin’s Investigational New Drug (IND) application for QRX003 in Peeling Skin Syndrome. Quoin submitted that IND on June 2, 2026, and it was the first IND ever submitted to the FDA for the disease.
  • Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.
  • The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study in a single subject. Significant improvements in skin appearance along with positive changes in pruritus and a number of quality-of-life measures have been recorded. Treatment is ongoing and has continued for more than 15 months, with no adverse events reported.
  • There is currently no approved treatment for Peeling Skin Syndrome.

“This is an important regulatory milestone for QRX003 and for a community that today has no approved treatment,” said Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals. “Quoin submitted the first IND ever filed with the FDA for Peeling Skin Syndrome, that IND was cleared in July, and QRX003 has now been granted Fast Track Designation for the disease. We expect to initiate our Phase 2/3 study in the second half of 2026, and we believe Fast Track status will allow us to work closely with the agency as we advance the first company-sponsored clinical study in this disease.”

Peeling Skin Syndrome Development Program

The planned Phase 2/3 study is expected to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe. In the study, QRX003 will be applied twice-daily to greater than 80% of patients’ body surface area (BSA) over a 48-week period, with an interim data review at 24 weeks. Quoin is targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028.

The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study. The subject has achieved improvements across key objective severity endpoints, including the Modified Ichthyosis Area Severity Index (M-IASI), Investigator’s Global Assessment (IGA) as well as pruritus and a pediatric dermatology-specific quality-of-life measure (CDLQI). Treatment is ongoing, and after continued dosing with QRX003 for over 15 months, no adverse events have been reported.

About Fast Track Designation

The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. A therapy granted Fast Track Designation may benefit from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met.

About Peeling Skin Syndrome (PSS)

Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.

About QRX003

QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug Designation in the European Union and Japan for Netherton Syndrome. QRX003 has also been granted Rare Pediatric Disease and Fast Track Designation by the FDA for Peeling Skin Syndrome. QRX003 lotion (4%) is currently being evaluated in Phase 2/3 whole-body clinical trials in patients with Netherton Syndrome. Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.

About Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others.

For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Forward-Looking Statements

The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Fast Track Designation facilitating development and expediting regulatory review of therapies addressing serious conditions with significant unmet medical need; plans to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026; Fast Track status allowing Quoin to work closely with the FDA to advance the first company-sponsored clinical study in Peeling Skin Syndrome; the study expecting to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe; QRX003 expected to be applied twice-daily to greater than 80% of a patients’ body surface area over a 48-week period, with an interim data review at 24 weeks; targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028; therapies granted Fast Track Designation benefiting from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Contacts

Jeff Ramson
jramson@pcgadvisory.com
Michael Myers
mmyers@quoinpharma.com

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Ashburn, Virginia, September 22nd, 2026, FinanceWire

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has No Approved Treatment

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. Peeling Skin Syndrome is a rare genetic skin disease for which there is currently no approved treatment.

Key Facts

  • Fast Track Designation applies to QRX003 for the treatment of Peeling Skin Syndrome.
  • This is the first ever Fast Track Designation granted for a Peeling Skin Syndrome therapy.
  • Peeling Skin Syndrome is the second indication for which QRX003 has received Fast Track Designation. The FDA granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome on March 11, 2026.
  • The designation follows FDA clearance in July 2026 of Quoin’s Investigational New Drug (IND) application for QRX003 in Peeling Skin Syndrome. Quoin submitted that IND on June 2, 2026, and it was the first IND ever submitted to the FDA for the disease.
  • Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.
  • The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study in a single subject. Significant improvements in skin appearance along with positive changes in pruritus and a number of quality-of-life measures have been recorded. Treatment is ongoing and has continued for more than 15 months, with no adverse events reported.
  • There is currently no approved treatment for Peeling Skin Syndrome.

“This is an important regulatory milestone for QRX003 and for a community that today has no approved treatment,” said Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals. “Quoin submitted the first IND ever filed with the FDA for Peeling Skin Syndrome, that IND was cleared in July, and QRX003 has now been granted Fast Track Designation for the disease. We expect to initiate our Phase 2/3 study in the second half of 2026, and we believe Fast Track status will allow us to work closely with the agency as we advance the first company-sponsored clinical study in this disease.”

Peeling Skin Syndrome Development Program

The planned Phase 2/3 study is expected to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe. In the study, QRX003 will be applied twice-daily to greater than 80% of patients’ body surface area (BSA) over a 48-week period, with an interim data review at 24 weeks. Quoin is targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028.

The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study. The subject has achieved improvements across key objective severity endpoints, including the Modified Ichthyosis Area Severity Index (M-IASI), Investigator’s Global Assessment (IGA) as well as pruritus and a pediatric dermatology-specific quality-of-life measure (CDLQI). Treatment is ongoing, and after continued dosing with QRX003 for over 15 months, no adverse events have been reported.

About Fast Track Designation

The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. A therapy granted Fast Track Designation may benefit from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met.

About Peeling Skin Syndrome (PSS)

Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.

About QRX003

QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug Designation in the European Union and Japan for Netherton Syndrome. QRX003 has also been granted Rare Pediatric Disease and Fast Track Designation by the FDA for Peeling Skin Syndrome. QRX003 lotion (4%) is currently being evaluated in Phase 2/3 whole-body clinical trials in patients with Netherton Syndrome. Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.

About Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others.

For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Forward-Looking Statements

The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Fast Track Designation facilitating development and expediting regulatory review of therapies addressing serious conditions with significant unmet medical need; plans to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026; Fast Track status allowing Quoin to work closely with the FDA to advance the first company-sponsored clinical study in Peeling Skin Syndrome; the study expecting to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe; QRX003 expected to be applied twice-daily to greater than 80% of a patients’ body surface area over a 48-week period, with an interim data review at 24 weeks; targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028; therapies granted Fast Track Designation benefiting from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Contacts

Jeff Ramson
jramson@pcgadvisory.com
Michael Myers
mmyers@quoinpharma.com

Why Starting Work at 14 Prepared William Stapleton to Sell a Company for $300 Million

  • William Stapleton, President and CEO of Iron Rock Payments in Frisco, Texas, shares how early work shaped his path from private banking to entrepreneurship.

How did working from age 14 influence your career?

Texas, USA, Sep 22, 2026, ZEX PR WIRE — “I have worked since I was 14 years old to support myself and used this work ethic into college,” Stapleton says. He grew up in a working-class household in Long Beach, California. His mother is from Ecuador and his father is of German and Polish descent. Starting work young built financial responsibility and shaped his approach to business.

He played varsity baseball and water polo while working through high school. He graduated with honors from Long Beach Wilson Classical High School near the top of his class. In college, he took an unpaid internship at Salomon Brothers while balancing his studies. “I graduated college with full honors, top of my class academically,” he says. He earned a double major in Rhetorical Theory and Global Economics from California State University, Long Beach in 2006.

What did you learn in private banking that helped you as an entrepreneur?

After graduation, Morgan Stanley Private Bank recruited Stapleton to work in New York. He later joined JPMorgan Chase, where he contributed to building what is now known as the Chase Private Client program. He spent approximately seven years in private banking and advisory roles.

Working with high-net-worth clients taught him how to manage relationships, assess risk, and structure solutions. Those skills transferred directly to running a business. Understanding client needs and delivering value became the foundation of his entrepreneurial approach.

How did you transition from banking to payments?

Stapleton founded PayFacto, a credit card processing company based in Montreal. He built the company from the ground up and grew it until Visa acquired it in 2019. The sale carried an estimated valuation of $300 million.

He did not wait long to start again. In 2012, he founded Iron Rock Payments, a credit card processing company based in Frisco, Texas. The company has been recognized as an Inc. 5000 company and employs 15 people. Stapleton serves as President and CEO.

What do businesses get wrong about payment processing?

Many businesses treat payment processing as a commodity. They focus only on rates and miss the bigger picture. The right processor can improve cash flow, reduce chargebacks, and provide data that drives decisions.

Stapleton emphasizes that service matters as much as price. Businesses need a partner who understands their industry and responds quickly when issues arise. A few basis points saved on fees mean nothing if downtime costs thousands in lost sales.

What lessons from your first exit did you apply to Iron Rock Payments?

Selling PayFacto taught Stapleton the importance of building systems that scale. He learned to hire people who are better than him in specific areas and to trust them. He also realized that culture drives retention and retention drives growth.

At Iron Rock Payments, he focused on creating processes that work whether the company has 5 employees or 50. He invests in technology that automates repetitive tasks so his team can focus on client relationships. He also prioritizes transparency with clients and employees.

What advice do you give to people thinking about starting a business?

Start before you feel ready. Waiting for the perfect moment means you will never start. Stapleton began working at 14 and took an unpaid internship in college because he wanted experience more than money.

He also advises entrepreneurs to stay close to their customers. The best product ideas come from listening to what clients actually need, not from guessing. Finally, he says to protect your reputation. Trust takes years to build and seconds to destroy.

If you do nothing else

  1. Start working as early as you can to build a strong work ethic and financial discipline.

  2. Take internships or entry-level roles that teach you skills, even if the pay is low or nonexistent.

  3. Spend time in an industry before you try to disrupt it so you understand how it really works.

  4. Build systems and processes that can scale as your business grows.

  5. Hire people who are stronger than you in areas where you are weak and trust them to do their jobs.

  6. Listen to your clients and let their needs guide your product and service decisions.

  7. Protect your reputation by delivering on promises and treating people with respect.

Share this Q&A with someone who is thinking about making the leap from employee to entrepreneur or who wants to understand how early work experience shapes long-term success.

About William Stapleton

William Stapleton is President and CEO of Iron Rock Payments, a credit card processing company based in Frisco, Texas. He founded the company in 2012 after selling his previous venture, PayFacto, to Visa in 2019 at an estimated valuation of $300 million. Before entering entrepreneurship, he worked in private banking at Morgan Stanley and JPMorgan Chase, where he contributed to creating the Chase Private Client program. He graduated with full honors from California State University, Long Beach with a double major in Rhetorical Theory and Global Economics.

Orange County Music and Dance names opening date for second campus, plans pre-K to 12 pathway

  • Orange County Music & Dance will open a second, 25,000-square-foot campus on Cowan Avenue in Irvine this November, adding conservatory and pre-conservatory programs and early childhood classes under new CEO Ralph Opacic.

A second building, a bigger promise

Santa Ana, California, Sep 22, 2026, ZEX PR WIRE — Orange County Music & Dance has bought a 25,000-square-foot building for $10.8 million to serve as its second campus. The purchase doubles the nonprofit’s footprint to nearly 50,000 square feet. It is scheduled to open in November, after renovations, minutes from OCMD’s current Irvine headquarters.

Ralph Opacic, who became OCMD’s chief executive last October, says the new space solves a problem the organization could not solve with its original building alone.

“We needed the space to truly be a comprehensive pre-K to 12 arts community music and dance school,” Opacic said.

What moves, what stays, what’s new

The Cowan Avenue campus will hold four new dance facilities, a large rehearsal space for ensembles such as band, orchestra, and musical theater, a second piano lab, a music production studio, and about 15 flexible rehearsal rooms.

Two new programs will launch there, starting a couple of months before the building opens. The first is a conservatory program: college preparatory, pre-professional training for high school students performing at an intermediate to advanced level. The second is a pre-conservatory program for sixth through eighth graders, built as a feeder into the high school track.

“It further strengthens the pathways available for those students who, at an early age, are seeking a premier experience that supports their goals,” Opacic said.

Early childhood music and dance programs for children 6 months to 5 years old will also open at the new site, along with OCMD’s adult evening programs. Discovery programs for kindergarten through fifth grade will stay at the existing Irvine headquarters. OCMD expects enrollment to grow by 400 students once the second campus is running.

Buying instead of building

OCMD had spent time planning a larger project at the Great Park before shifting course this year. Buying an existing building instead of constructing a new one cut an 18-month timeline down to six, according to Opacic, and let OCMD acquire the property without taking on debt.

That change in plan is why the Cowan Avenue building is opening this fall rather than years from now. Opacic points to the shorter timeline as the reason the new conservatory programs can start enrolling students this year instead of waiting for a multi-year build.

A pathway with no gap in it

Opacic has spent decades building programs for young performers, first at Orange County School of the Arts and now at OCMD. The phrase he uses for what the Cowan Avenue campus is meant to do is “womb to tomb.”

“The program is going to be a one-stop shop to serve families that have children, from womb to tomb,” Opacic said.

In practice, that means a child can start in an infant music class, move into discovery programs in elementary school, enter the pre-conservatory track in middle school, and finish in the conservatory program through high school, all inside one organization. Adult classes mean the pathway does not stop at graduation either.

Opacic has hired several new staff members for the conservatory programs, including some who previously worked with him at his former school.

What the expansion is meant to fix

The new building is not simply more room. It lets OCMD run programs it could not run before: specialized group and technique classes, musicianship and theory training, rehearsal and repertoire-based work, individualized coaching, and performance opportunities across music genres and dance styles. Those are the pieces that turn private lessons into a conservatory track, and OCMD did not have the space to offer them until now.

Opacic says the timing matters because families are asking for exactly this kind of continuous program, one that does not force a student to leave for a different school once they outgrow beginner classes.

“How fantastic would it be to start getting kids engaged and involved in music as infants or toddlers, and then be involved in their full music development?” Opacic said.

To read more, visit the website here.

About Ralph Opacic

Ralph S. Opacic, Ed.D. is chief executive of Orange County Music & Dance, a performing arts nonprofit headquartered in Irvine, California. He founded and previously led Orange County School of the Arts in Santa Ana, California, and has spent more than 25 years building arts education and training programs for young performers.

David Wayne Fish makes a personal pledge: one season, one sport, no missed games

California, USA, Sep 22, 2026, ZEX PR WIRE — David Wayne Fish is putting a specific commitment on the record. With six kids moving through baseball, football, and tennis across overlapping seasons, he says the easiest thing to let slip is presence. So he is naming the standard out loud.

“If one of my kids has a game or a practice, someone from this family is there,” Fish says. “That’s the whole pledge. It sounds simple because it should be simple. The hard part is building a life where you can actually keep it.”

Fish runs healthcare and wellness companies as a consultant and CEO, work that does not pause for a Tuesday scrimmage. He is not pretending otherwise. The pledge is not about having endless free time. It is about deciding in advance what wins when a calendar conflict shows up.

Why he is saying it publicly

Fish has coached football, baseball, and helped organize tennis for years. He says most parents do not fail their kids through some dramatic absence. They fail them through a hundred small ones that never get flagged as decisions at all.

“Nobody skips a game and thinks of it as a broken promise,” he says. “It just looks like a scheduling problem. I wanted to write my own rule down so it stops being negotiable case by case.”

He credits his own father, and the model of family life he grew up with in Michigan, for the instinct behind this. Fish says he was raised around the idea that a father’s job includes showing up, not just providing.

What the commitment actually covers

The pledge Fish is making has a few concrete parts:

Every game gets a family face in the stands. Not every game gets David personally, with six kids and overlapping seasons that is not realistic, but every game gets someone: him, his wife, or another family member who can stand in.

Coaching commitments get finished, not started. Fish says he does not sign up to coach a season and then quietly hand it off when work gets busy. If he takes a team, he finishes the season.

Conflicts get resolved before the week starts, not during it. Fish says he sits down weekly and maps which kid has what, so trade-offs get made on a Sunday with a clear head instead of on a Wednesday in a parking lot.

“I’d rather lose an hour on Sunday mapping the week than lose a moment at my kid’s game because I’m distracted by something I should have planned around,” he says.

What he is asking of himself, not other parents

Fish is careful to frame this as his own standard, not a lecture. He is not telling other families how to run their weeks.

“I’m not in a position to tell another parent what their life allows,” he says. “I know what mine allows, and I know where I’ve cut corners before without meaning to. This is me closing that gap for myself.”

He says the pledge will get tested immediately, since his kids’ seasons rarely line up cleanly. Two games at the same hour, in two different towns, is not a hypothetical for his family. It happens.

“When that comes up, the answer isn’t ‘we’ll figure it out.’ The answer is already written down: someone from this family goes to each one,” Fish says. “I’d rather have made that call in October than try to make it in the car in March.”

Holding himself to it

Fish says he plans to track the pledge the same plain way he tracks anything else he takes seriously: a simple log of games, and who from the family was there. No app, no public scoreboard, just a habit he intends to keep himself honest about.

“If I say I’m going to do something for my kids, I want a way to check whether I actually did it,” he says. “That’s the only accountability that’s ever mattered to me.”

To read more, visit the website here.

About David Wayne Fish

David Wayne Fish is an entrepreneur based in Laguna Niguel, California. He works as a CEO and consultant to healthcare and wellness companies. Outside that work, he coaches youth football and baseball, helps organize tennis programs, and is the father of six children active in sports.

Honnas Veterinary Introduces a Self-Check Guide for Austin Pet Owners

  • Honnas Veterinary is releasing a short self-check list to help Austin pet owners decide when a visit is worth scheduling, built around the same questions its team asks during exams.

A simple set of questions before the appointment

Texas, USA, Sep 22, 2026, ZEX PR WIRE — Honnas Veterinary, a female-owned veterinary practice in Austin, Texas, is publishing a self-check list for pet owners. The list is meant to be used at home, before a call to the clinic, so owners can organize what they have noticed and share it clearly with a doctor.

The practice built the list from the questions its veterinarians already ask new and returning patients. Dr. Cheri Honnas, founder of Honnas Veterinary, said the goal is to give owners a starting point rather than a diagnosis.

“Owners usually know something is different about their pet before they can put it into words,” Dr. Honnas said. “This list helps them organize what they are seeing so our team can act on it faster.”

What the self-check covers

The list is organized into four short sections:

Eating and drinking. Has the amount changed in either direction over the past week? Has the pet stopped finishing meals it used to eat without trouble?

Energy and movement. Is the pet resting more than usual? Is it slower to get up, reluctant to jump, or limping on and off?

Bathroom habits. Any change in frequency, color, or straining should be written down, including the day it started.

Coat, skin, and weight. Owners are asked to run a hand along the pet’s back and sides. New lumps, bald patches, or a change in body shape are worth noting even if the pet seems otherwise fine.

Each section asks the owner to write down when the change started and whether it has gotten better, worse, or stayed the same. That timeline is often more useful to a veterinarian than a single description of symptoms.

Why the practice built it this way

Honnas Veterinary sees over 1,500 patients a month across a team of five doctors. That volume has shown the practice which details tend to matter most in an exam room and which ones owners often leave out until asked directly.

“We hear a lot of ‘he’s just been off lately,’” Dr. Honnas said. “That is a real observation, but it is not something we can act on right away. The self-check gives owners a way to turn ‘off’ into specifics.”

The clinic is Fear Free certified, and its staff apply Fear Free handling techniques during visits to help reduce stress for pets. The self-check list is meant to work alongside that approach: the more clearly an owner can describe what changed at home, the shorter and calmer the exam can be.

How the list will be used

Honnas Veterinary plans to make the self-check available to clients as a printed handout and as part of new patient materials. Owners can also use it on their own, whether or not they are due for a visit, as a way to keep a running record between checkups.

The practice is not positioning the list as a replacement for an exam. Instead, it is meant to make the conversation with a veterinarian more direct.

“None of this replaces a hands-on exam,” Dr. Honnas said. “But when an owner walks in with a clear timeline instead of a vague feeling, we can usually get to an answer faster. That matters for the pet and for the family.”

Availability

Honnas Veterinary offers free new patient exams for pet owners in the Austin area. The self-check list is part of the practice’s broader effort to make veterinary care more accessible, alongside its existing scheduling and exam options.

To read more, visit the website here.

About Honnas Veterinary

Honnas Veterinary is a locally owned, female-owned veterinary practice in Austin, Texas, founded by Dr. Cheri Honnas in 2023. The practice has grown to a team of five veterinarians and sees more than 1,500 patients each month. Honnas Veterinary is Fear Free certified and offers wellness exams, vaccinations, surgery, dental care, diagnostics, and emergency treatment from its clinic in Austin.

Zeagoo’s 13th Anniversary Celebration Rocks Today: Partnering with Maye Musk to Honor the New Beginnings of Mature Women

New York, USA / Timesnewswire / September 22, 2026 – Today marks a monumental milestone as Zeagoo, an apparel brand dedicated to the mature women’s market, officially kicks off its highly anticipated 13th Anniversary Celebration!

Thirteen years of dedication have not only shaped the brand’s growth and evolution, but also built up to this grand annual moment. Centered on the empowering theme “13th Anniversary: It’s Not Too Late”, Zeagoo releases a bold, inspiring call to women everywhere on this special day: it is never too late to transform, explore, and relentlessly pursue your true self!

Thirteen Years of Dedication, Embracing Timeless Grace with Maye Musk

Over the past 13 years, Zeagoo has consistently attuned itself to the real needs and evolving aesthetics of mature women, delivering styling experiences that seamlessly blend comfort with personal empowerment.

As Zeagoo reaches its landmark 13th anniversary, the brand considers itself truly privileged to walk hand in hand with legendary supermodel and global style icon Maye Musk. More than a collaborator, Maye Musk stands as a true soulmate to the brand—her poised confidence, resilience, and boundless vitality brilliantly echoing Zeagoo’s core philosophy: that age is never a boundary, but a lifelong gift endowing women with unmatched grace. Celebrating 13 years together, this profound connection transcends conventional fashion; it elevates an age-defying mindset into a lifestyle, empowering mature women worldwide to embrace every moment with unwavering elegance and purpose.

Unveiling New Autumn Additions to the “Maye’s Picks” Collection: Fashion as a Narrative of Strength

Following the enthusiastic response to the “Maye’s Picks” Collection, Zeagoo is celebrating its 13th anniversary today by officially dropping its brand-new Autumn Capsule within the collection. Designed to help mature women navigate the seasonal transition with effortless sophistication, this latest drop expands the line with versatile knitwear, soft tops, and polished layering pieces.

Among the newly released autumn highlights featured in the collection:

The Classic Crew-Neck Long-Sleeve Knit Sweater: Crafted like a gentle embrace forged by time, this autumn staple is made from 100% viscose to deliver lightweight breathability and an ultra-soft touch. Free of unnecessary clutter, its tailored cut seamlessly flatters diverse silhouettes. More than just a garment, it serves as a subtle testament to self-assurance—whether commanding an office room or enjoying a relaxed autumn weekend, it allows women to radiate quiet strength and unrestrained grace.

The Casual Raglan-Sleeve Turtleneck Sweater: Wrapped in a soft, romantic pink hue, this sweater brings effortless warmth and modern elegance to cool autumn days. Its relaxed raglan-sleeve design creates a soft shoulder line for comfortable movement, while the cozy turtleneck adds a refined, cozy touch. Designed with versatile minimalism, it gently flatters every silhouette—empowering women to navigate crisp autumn breezes with grace and effortless confidence.

Explore the full “Maye’s Picks” autumn line live starting today, inviting mature women everywhere to discover their next favorite wardrobe statement.

A Vibrant New Starting Point: Empowering Mature Women to Shine

Wrapping up 13 incredible years is merely the prologue—endless possibilities begin today. Driven by the energetic slogan “It’s Not Too Late”, Zeagoo aims to ignite a spark in mature women everywhere on this celebration day, urging them to step boldly into exciting new chapters of life.

Moving forward, Zeagoo will continue to stand alongside every mature woman, empowering them to shine with brilliant confidence at every new beginning.

Zeagoo
Charlotte Liu
pr@zeagoo.com
New York, US
https://zeagoo.com

2026 Fall Men’s Fashion Trend: Unlock Sophistication in Relaxed Fit — COOFANDY Builds a Relaxed Wardrobe for Mature Men

New York, USA / Timesnewswire / September 22, 2026 – In fall 2026, men’s fashion is quietly undergoing a “tailoring” revolution: tight slim fits are stepping back, while relaxed silhouettes and mature casual styles take center stage. How to pull off a “loose fit” with sophistication instead of looking slouchy has become a hot topic in North American fashion circles this season.

The core theme this season is balance — catering to commutes, weekend gatherings and autumn outings. The look should not be overly formal yet more refined than ordinary casual wear. The key to striking this balance lies in fabric drape and clean tailoring, and COOFANDY’s new seasonal pieces offer just the solution.

Refined Top Staple: Long-Sleeve Shirt With Understated Stylish Details

For your upper-body foundation, look no further than COOFANDY men’s button-down long-sleeve shirt. Crafted from 70% polyester, 27% viscose and 3% spandex, this light green shirt is lightweight, breathable and skin-friendly. It features a casual tailored fit with no restrictive fasteners, while plaid accents line the inner collar and cuffs to instantly add depth to your look. These seemingly subtle touches are what make outfits feel elevated yet wearable.

Streamlined Bottom Anchor: Casual Pants Blending Drape and Practicality

The visual anchor for your lower half is COOFANDY men’s casual jogger pants. Made of a 95% polyester and 5% spandex blend, the fabric offers great stretch and excellent drape. Its signature elastic waistband and open hem break away from the sloppy vibe of traditional sweatpants, with two deep side pockets plus a back pocket for everyday functionality. Paired with a simple T-shirt, it effortlessly creates a polished yet laid-back everyday look for the urban mature man.

Multiple Styling Options: Build a Versatile Autumn Wardrobe for Men

For modern men with refined taste, wardrobes do not need excess pieces. With highly versatile trousers and a thoughtfully detailed shirt, COOFANDY precisely addresses the core demands of fall men’s fashion: comfort, versatility, propriety and composure. This autumn, let your style embrace ease and use texture to define the sophisticated daily look of the mature man.

This season’s premium pieces are now fully available. Head to COOFANDY’s official store to explore more 2026 fall new arrivals and unlock your own autumn composure.

For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

COOFANDY

Charlotte Liu

pr@coofandy.com

New York, US

https://coofandy.com

Whispp Appoints Former Dolby Executive Andreas Spechtler as CEO

Whispp, the Dutch deep-tech company developing real-time, on-device Voice Reconstruction AI, announced the appointment of Former Dolby executive Andreas Spechtler as Chief Executive Officer and member of the Management Board.Founder Joris Castermans transitions to Chief Marketing Officer and will continue to lead Whispp’s vision, category development, and assistive mission.

LEIDEN, Netherlands, 22nd Sep 2026 – Whispp, the Dutch deep-tech company developing real-time, on-device Voice Reconstruction AI, today announced the appointment of Andreas Spechtler as Chief Executive Officer and member of the Management Board.

Andreas Spechtler, a former President of Dolby International and previously Member of the Board  at Whispp, will assume responsibility for the company’s strategy, operations, commercial growth and organizational development. His appointment comes as Whispp enters its next phase, focused on adopting its technology into mobile devices, PCs and wearables through partnerships with device manufacturers, semiconductor companies and global communication providers and platforms.

Joris Castermans, who founded Whispp and has led the company as CEO since 2020, will remain part of the leadership team as Management Board member and Chief Marketing Officer. In this role, he will lead Whispp’s global marketing, brand strategy, category development, strategic communications and assistive mission.

“Andreas combines extensive global experience in audio technology with a strong understanding of international markets and the partnerships needed to bring new technology into smartphones, PCs and wearables,” said Joris Castermans. “He has already made an important contribution to Whispp’s direction as Chief Strategy Advisor and board member. This leadership structure allows Andreas to focus on scaling the company while I continue to develop the vision, mission and Voice Reconstruction AI category that Whispp was built around.”

Andreas brings extensive international experience in audio technology, innovation and business development. He previously served as President of Dolby International and Regional Vice President Dolby EMEA , where he helped expand Dolby’s business across cinema, broadcast, electronic media and communications.

“Joris, Akash and the Whispp team have built a distinctive technology around the powerful human mission to give the best voice to everyone,” said Andreas Spechtler. “Whispp addresses a clear gap in the voice technology market. Our next step is to turn that innovation foundation into scalable products  and long-term industry partnerships. I look forward to working with Joris, Akash, the Whispp  team and our partners to bring Voice Reconstruction AI into the devices and communication experiences people use every day.”

Whispp’s patented audio-to-audio technology converts whispered, voiceless and affected speech into a person’s clear and natural voice in real-time. The technology runs entirely on the device and is designed to preserve characteristics such as accent, intonation, and speaker identity.

Whispp was founded by Joris Castermans in 2020, inspired by his personal experience with severe stuttering and his ambition to help people communicate in their own natural voice. Akash Raj Komarlu is Co-founder and has led the development of the company’s proprietary Voice Reconstruction AI.

Under Joris’ leadership, Whispp expanded its technology, team, intellectual property portfolio and international partner network. The company has received recognition from TIME Best Inventions, CES Innovation Award and Forbes Accessibility 100 for its technological innovation and human impact.

The leadership transition follows Whispp’s recent €5 million financing round. The funding supports further development of its AI models, new product development, expansion of its intellectual property portfolio and collaborations with global device manufacturers and semiconductor partners.

For more information see: https://www.whispp.com/ and http://www.whispp.com/blog/whispp-appoints-former-dolby-executive-andreas-spechtler-as-ceo

Media Contact

Organization: Whispp

Contact Person: Joris Castermans

Website: https://www.whispp.com/

Email:
joris@whispp.com

Contact Number: +31651234840

Country: Netherlands

Release id: 49318

The post Whispp Appoints Former Dolby Executive Andreas Spechtler as CEO appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

MEXC Launches “Real Stocks, Real Friends” with Rewards for Bringing Friends to Wall Street

Mutsamudu, Comoros, September 22nd, 2026, Chainwire

MEXC, a pioneer in 0-fee digital asset trading, has launched its “Real Stocks, Real Friends”, allowing users to bring their friends to Wall Street through RealStocks and earn rewards. Building on MEXC’s previous “Trade Wall Street, Without Walls, the event reflects MEXC’s efforts to lower barriers to the U.S. stock market for crypto-native users.

MEXC previously launched the “Trade Wall Street, Without Walls” campaign to help users break through five traditional barriers to stock market participation. These include the Access Wall, Fee Wall, Time Wall, Capital Wall and Direction Wall, in which MEXC addresses through its products, trading infrastructure and market access. MEXC’s efforts extend beyond lowering these barriers. Its recent initiatives also help users better understand markets, identify their trading preferences and explore more ways to participate. Opportunity Compass provides structured education across global markets, asset classes, market trends, emerging opportunities and risk, while “Discover Your Wall Street DNA” helps users identify their trading styles and explore stock products aligned with their preferences. The “Real Stocks, Real Friends” further extends this approach through an invitation-based model, allowing existing users to invite friends to discover RealStocks and explore the U.S. stock market. Inviters can earn rewards, while qualified invited users can receive additional benefits by completing the required activities.

The “Real Stocks, Real Friends” Event runs from September 10 to October 15, 2026 (UTC). During the event, users can invite friends to open a RealStocks account and complete the required tasks. When an invited friend completes the required RealStocks tasks, including a net purchase of at least 100 USDT and a three-day holding period, the inviter can receive a reward. Qualified invited users can also unlock a Futures Bonus for both the inviter and the invited user after completing the required futures task.

RealStocks is an innovative cross-market trading product launched by MEXC in collaboration with regulated brokerage partners, providing crypto-native users with access to real U.S. stocks and ETFs. The product supports more than 7,000 U.S.-listed stocks and ETFs, allowing users to purchase and hold real shares, with applicable shareholder benefits including dividend eligibility.

As a one-stop trading platform, MEXC also provides multiple ways to participate in the stock market across different stages. Its Stock Ecosystem spans Pre-IPO, IPO and Post-IPO opportunities, including Pre-IPO Futures, Pre-IPO Launchpad, IPO Launchpad, IPO Express, RealStocks, Tokenized Stocks and Stock Futures. Selected products also offer features such as 0-fee trading, extended or around-the-clock market access, and the ability to take both long and short positions. These options create more ways for users to participate in the stock market.

For more details and to participate in the “Real Stocks, Real Friends”, visit the MEXC official event page.

About MEXC

Founded in 2018, MEXC is a leading global multi-asset trading platform built as your 0-fee gateway to infinite opportunities. Serving users across 170+ markets, MEXC provides simple and efficient access to crypto, stocks, tokenized assets, derivatives, and a growing range of TradFi-linked opportunities through one account and one gateway.

With 0 trading fees, deep liquidity, broad asset coverage, and a high-performance trading experience, MEXC is designed for retail users who want to discover earlier, act faster, and trade with fewer barriers. As crypto and traditional finance continue to converge, MEXC is committed to making global opportunities more accessible, helping users trade freely and MEXCmize every opportunity.

MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

Risk Disclaimer:

This content does not constitute investment advice. Given the volatility of financial markets, including digital assets, tokenized assets, and traditional financial products, investors should carefully assess market conditions, underlying asset fundamentals, and potential financial risks before making any investment or trading decisions.

Contact

MEXC PR team
media@mexc.com